Research ArticleOriginal Research

Intermittent Aerosol Delivery to the Lungs During High-Flow Nasal Cannula Therapy

Laleh Golshahi, P Worth Longest, Mandana Azimi, Aamer Syed and Michael Hindle
Respiratory Care October 2014, 59 (10) 1476-1486; DOI: https://doi.org/10.4187/respcare.02903

Article Figures & Data

Figures

  • Fig. 1.
    Fig. 1.

    The experimental setup for in vitro controlled condensational growth. A: Schematic diagram. B: Excipient-enhanced growth (EEG) nasal cannula. C: Enhanced condensational growth (ECG) nasal cannula. D: Nose-mouth-throat (NMT) model, including the facial structure, shown with EEG nasal cannula.

  • Fig. 2.
    Fig. 2.

    A: Intermittent 2-s aerosol delivery. B: Intermittent 1-s aerosol delivery during simulation of breathing profile 1.

  • Fig. 3.
    Fig. 3.

    Amount of drug captured at the outlet (ex-NMT) of the nose-mouth-throat (NMT) model. A: Delivered dose as a percentage of the emitted dose in the enhanced condensation growth (ECG) delivery modes and B: excipient enhanced growth (EEG) delivery modes. Data are shown as mean ± SD.

  • Fig. 4.
    Fig. 4.

    A: Respiration losses as a percentage of the emitted dose in all enhanced condensation growth (ECG) delivery modes and B: all excipient enhanced growth (EEG) delivery modes. Data are shown as mean ± SD.

Tables

  • Table 1.
  • Table 2.
  • Table 3.
  • Table 4.
  • Table 5.
Back to top

In this issue

 

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Related Articles

Cited By...

Keywords